A detailed history of Dafna Capital Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 256,717 shares of RCUS stock, worth $4.1 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares
256,717
Previous 253,217 1.38%
Holding current value
$4.1 Million
Previous $3.86 Million 1.79%
% of portfolio
1.01%
Previous 0.99%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $47,915 - $63,035
3,500 Added 1.38%
256,717 $3.93 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $313,685 - $397,320
21,500 Added 9.28%
253,217 $3.86 Million
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $14,830 - $20,180
-1,000 Reduced 0.43%
231,717 $4.37 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $134,300 - $196,300
10,000 Added 4.49%
232,717 $4.44 Million
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $52,860 - $70,620
-3,000 Reduced 1.33%
222,717 $4 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $856,985 - $1.11 Million
50,500 Added 28.82%
225,717 $4.58 Million
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $526,680 - $763,950
33,000 Added 23.2%
175,217 $3.2 Million
Q4 2022

Feb 14, 2023

SELL
$19.7 - $35.71 $719,050 - $1.3 Million
-36,500 Reduced 20.42%
142,217 $2.94 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $209,070 - $270,630
-9,000 Reduced 4.79%
178,717 $4.68 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $732,275 - $1.6 Million
42,500 Added 29.27%
187,717 $4.76 Million
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $810,251 - $1.17 Million
28,017 Added 23.91%
145,217 $4.58 Million
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $203,970 - $315,055
-6,500 Reduced 5.25%
117,200 $4.74 Million
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $107,720 - $150,720
4,000 Added 3.34%
123,700 $4.31 Million
Q2 2021

Aug 16, 2021

BUY
$22.75 - $35.77 $1.41 Million - $2.22 Million
62,100 Added 107.81%
119,700 $3.29 Million
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $209,280 - $331,120
8,000 Added 16.13%
57,600 $1.62 Million
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $382,500 - $728,100
-22,500 Reduced 31.21%
49,600 $1.29 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $618,898 - $1.62 Million
44,302 Added 159.37%
72,100 $1.78 Million
Q1 2020

May 15, 2020

BUY
$8.78 - $19.28 $244,066 - $535,945
27,798 New
27,798 $386,000
Q2 2018

Aug 13, 2018

SELL
$12.24 - $17.05 $91,800 - $127,875
-7,500 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$15.44 - $17.71 $115,800 - $132,825
7,500 New
7,500 $116,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.